To evaluate the role of intravitreal ranibizumab, injected at the time of cataract surgery on the progression of postoperative diabetic macula edema (PME) in non-proliferative diabetic retinopathy (NPDR).


Multi-center, prospective randomized study.


80 Patients with NPDR and cataract were randomized to 40 only cataract surgery (Sham group) or 40-cataract surgery plus intraoperative ranibizumab injection (ranibizumab injection group). PME was assessed at 1, 3 and 6-month follow-up with optical coherence tomography (OCT). Best-corrected visual acuity (BCVA) was assessed at 1, 3 and 6-month follow-up. We defined the clinically meaningful PME as an increase of CFT >30% from preoperative baseline by OCT. Postoperative CFT and BCVA were compared between sham and ranibizumab injection group during 6 month.


71 patients have finished this randomized study. At 1 month, mean preoperative CFT was 253um in ranibizumab injection group, and 250um in sham injection group. PME occurred in 4(10.5%) of 38 eyes in ranibizumab injection group and 11(33.3%) of 31 eyes in sham injection group. (p=0.019) At 6-month follow-up, ranibizumab injection group showed better visual acuity than sham injection group. (p=0.031) There was one case of mild postoperative vitreous hemorrhage in ranibizumab injection group.


In patients with NPDR and cataract, intravitreal ranibizumab injection at the time of cataract surgery could prevent the clinically meaningful PME at 1 month, and finally showed better visual acuity at 6-month follow-up.